

9. Polo-Hernández E, De Castro F, García-García AG, Taberero A, Medina JM. Oleic acid synthesized in the periventricular zone promotes axonogenesis in the striatum during brain development. *J Neurochem*. 2010; 114(6): 1756-66.
10. García-García AG, Polo-Hernández E, Taberero A, Medina JM. Alpha-fetoprotein (AFP) modulates the effect of serum albumin on brain development by restraining the neurotrophic effect of oleic acid. *Brain Res*. 2015; 1624: 45-58.
11. Haydar TF, Blue ME, Molliver ME, Krueger BK, Yarowsky PJ. Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome. *J Neurosci*. 1996; 16(19): 6175-82.
12. Laffaire J, Rivals I, Dauphinot L, Pasteau F, Wehrle R, Larrat B, et al. Gene expression signature of cerebellar hypoplasia in a mouse model of Down syndrome during postnatal development. *BMC Genomics*. 2009; 10: 138.
13. Roper RJ, Baxter LL, Saran NG, Klinedinst DK, Beachy PA, Reeves RH. Defective cerebellar response to mitogenic Hedgehog signaling in Down [corrected] syndrome mice. *Proc Natl Acad Sci U S A*. 2006; 103(5): 1452-6.
14. Altafaj X, Dierssen M, Baamonde C, Martí E, Visa J, Guimerà J, et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. *Hum Mol Genet*. 2001; 10(18): 1915-23.
15. Arqué G, Fotaki V, Fernández D, Martínez de Lagrán M, Arbonés ML, Dierssen M. Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). *PLoS One*. 2008; 3(7): e2575.
16. Cheon MS, Kim SH, Fountoulakis M, Lubec G. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. *J Neural Transm Suppl*. 2003(67): 225-34.
17. Tejedor FJ, Hammerle B. MNB/DYRK1A as a multiple regulator of neuronal development. *FEBS J*. 2011; 278(2): 223-35.
18. Saud K, Arriagada C, Cárdenas AM, Shimahara T, Allen DD, Caviedes R, et al. Neuronal dysfunction in Down syndrome: contribution of neuronal models in cell culture. *J Physiol Paris*. 2006; 99(2-3): 201-10.
19. Opazo P, Saud K, de Saint Pierre M, Cárdenas AM, Allen DD, Segura-Aguilar J, et al. Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: An animal model of down syndrome. *J Neurosci Res*. 2006; 84(6): 1303-10.
20. Hijazi M, Fillat C, Medina JM, Velasco A. Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. *Exp Neurol*. 2013; 239: 229-34.
21. Bento-Abreu A, Taberero A, Medina JM. Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons. *J Neurochem*. 2007; 103(3): 871-81.
22. Rodríguez-Rodríguez RA, Taberero A, Velasco A, Lavado EM, Medina JM. The neurotrophic effect of oleic acid includes dendritic differentiation and the expression of the neuronal basic helix-loop-helix transcription factor NeuroD2. *J Neurochem*. 2004; 88(5): 1041-51.
23. Allen DD, Martín J, Arriagada C, Cárdenas AM, Rapoport SI, Caviedes R, et al. Impaired cholinergic function in cell lines derived from the cerebral cortex of normal and trisomy 16 mice. *Eur J Neurosci*. 2000; 12(9): 3259-64.
24. Ozand PT, Hawkins RL, Collins RM Jr, Reed WD, Baab PJ, Oster-Granite ML. Neurochemical changes in murine trisomy 16: delay in cholinergic and catecholaminergic systems. *J Neurochem*. 1984; 43(2): 401-8.
25. Sweeney JE, Höhmann CF, Oster-Granite ML, Coyle JT. Neurogenesis of the basal forebrain in euploid and trisomy 16 mice: an animal model for developmental disorders in Down syndrome. *Neuroscience*. 1989; 31(2): 413-25.
26. Fiedler JL, Epstein CJ, Rapoport SI, Caviedes R, Caviedes P. Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). *Brain Res*. 1994; 658(1-2): 27-32.
27. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, et al. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. *Brain Res*. 1983; 280(1): 119-26.
28. Kish S, Karlinsky H, Becker L, Gilbert J, Rebbetoy M, Chang LJ, et al. Down's syndrome individuals begin life with normal levels of brain cholinergic markers. *J Neurochem*. 1989; 52(4): 1183-7.
29. Lubec B, Yoo BC, Dierssen M, Balic N, Lubec G. Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotonergic innervation. *J Neural Transm Suppl*. 2001; 61: 303-10.
30. Massarelli R, Ferret B, Sorrentino G, Hattori H, Kanfer JN. Choline acetyltransferase-like activity bound to neuronal plasma membranes. *Neurochem Res*. 1988; 13(12): 1193-8.
31. Hattori H, Kanfer JN, Massarelli R. Stimulation of phospholipase D activity and indication of acetylcholine synthesis by oleate in rat brain synaptosomal preparations. *Neurochem Res*. 1987; 12(8): 687-92.
32. Machová E, Málková B, Lisá V, Nováková J, Dolezal V. The increase of choline acetyltransferase activity by docosahexaenoic acid in NG108-15 cells grown in serum-free medium is independent of its effect on cell growth. *Neurochem Res*. 2006; 31(10): 1239-46.
33. Murphy EJ, Schapiro MB, Rapoport SI, Shetty HU. Phospholipid composition and levels are altered in Down syndrome brain. *Brain Res*. 2000; 867(1-2): 9-18.
34. Shah SN. Fatty acid composition of lipids of human brain myelin and synaptosomes: changes in phenylketonuria and Down's syndrome. *Int J Biochem*. 1979; 10(6): 477-82.
35. Elul R, Hanley J, Simmons JQ 3rd. Non-Gaussian behavior of the EEG in Down's syndrome suggests decreased neuronal connections. *Acta Neurol Scand*. 1975; 51(1): p. 21-28.
36. Hijazi M, Medina JM, Velasco A. Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A. *Mol Neurobiol*. 2016.
37. Medina JM, Taberero A. Astrocyte-synthesized oleic acid behaves as a neurotrophic factor for neurons. *J Physiol Paris*. 2002; 96(3-4): 265-71.
38. Lopez S, Bermudez B, Montserrat-de la Paz S, Jaramillo S, Varela LM, Ortega-Gomez A, et al. Membrane composition and dynamics: A target of bioactive virgin olive oil constituents. *Biochim Biophys Acta*. 2014; 1838(6): 1638-56.
39. Vance DE. Physiological roles of phosphatidylethanolamine N-methyltransferase. *Biochim Biophys Acta*. 2013; 1831(3): 626-32.
40. Planque C, Dairou J, Noll C, Bui LC, Ripoll C, Guedj F, et al. Mice deficient in cystathionine beta synthase display increased Dyrk1A and SAHH activities in brain. *J Mol Neurosci*. 2013; 50(1): 1-6.